Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057053 · ClinicalTrials.gov registry record · Early Phase 1
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
A Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04057053 is a Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 10 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04057053, a Early Phase 1 study of Cataract and Fuchs Endothelial Dystrophy, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.
Conditions Studied
Interventions
- DRUG Netarsudil 0.02% Ophthalmic Solution
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-10-02 |
| Est. Completion | 2020-12-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04057053
The ClinicalTrials.gov registry entry for NCT04057053 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (96% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Netarsudil 0.02% Ophthalmic Solution is the first listed.
NCT04057053 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04057053 about?
NCT04057053 is a clinical study titled "Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty". Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such as baseline age, pachymetry, or endothelial cell count influence response to Netarsudil.
What is the current status of trial NCT04057053?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-10-02. Estimated completion is 2020-12-20.
What conditions does trial NCT04057053 study?
This clinical trial studies the following conditions: Cataract, Fuchs Endothelial Dystrophy.
What interventions are being tested in trial NCT04057053?
The interventions under investigation include: Netarsudil 0.02% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04057053?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04057053 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%
RECRUITING · Early Phase 1
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.